Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's disease.

<h4>Background</h4>Ideally, disease modifying therapies for Alzheimer disease (AD) will be applied during the 'preclinical' stage (pathology present with cognition intact) before severe neuronal damage occurs, or upon recognizing very mild cognitive impairment. Developing and judiciously administeri... View More